New Additions to Drugs.com for 2011
We update the Drugs.com database on a regular cycle. The following new drug information was added in 2011:
Dec 20, 2011 - Edarbyclor (azilsartan medoxomil and chlorthalidone) is a fixed-dose combination of an angiotensin II receptor blocker (ARB) and a diuretic, indicated for the treatment of hypertension.
Dec 13, 2011 - Anturol (oxybutynin) is an anticholinergic transdermal gel formulation indicated for the management of overactive bladder.
Nov 30, 2011 - Forfivo XL (bupropion) is a high-strength formulation of the aminoketone antidepressant bupropion (contained in Wellbutrin) indicated for the treatment of major depressive disorder.
Nov 24, 2011 - Intermezzo is a low dose, fast acting, sublingual formulation of the hypnotic agent zolpidem, indicated for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep.
Nov 20, 2011 - Eylea (aflibercept) is a VEGF inhibitor indicated for the treatment of patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.
Nov 20, 2011 - Erwinaze (asparaginase Erwinia chrysanthemi) is an antineoplastic agent used to treat patients with acute lymphoblastic leukemia (ALL) who have developed an allergy (hypersensitivity) to E. coli derived asparaginase and pegapargase chemotherapy drugs.
Nov 16, 2011 - Jakafi (ruxolitinib) is a Janus kinase (JAK) inhibitor indicated for the treatment of myelofibrosis, polycythemia vera, and graft versus host disease.
Oct 31, 2011 - Exparel (bupivacaine liposome injectable suspension) is a long-acting non-opioid local analgesic for the management of postsurgical pain.
Oct 26, 2011 - Ferriprox (deferiprone) is an iron chelator indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes and sickle cell disease.
Oct 25, 2011 - Onfi (clobazam) is a benzodiazepine antiepileptic drug for the treatment of patients with Lennox-Gastaut syndrome (LGS).
Oct 7, 2011 - Juvisync (simvastatin and sitagliptin) is an HMG-CoA reductase inhibitor (statin) and dipeptidyl peptidase-4 (DPP-4) inhibitor fixed dose combination for the treatment of high cholesterol and type 2 diabetes.
Aug 26, 2011 - Xalkori (crizotinib) is an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are ALK-positive.
Aug 26, 2011 - Firazyr (icatibant) is a selective B2 bradykinin receptor antagonist indicated for the treatment of acute attacks of hereditary angioedema.
Aug 26, 2011 - Adcetris (brentuximab vedotin) is a CD30-directed antibody-drug conjugate (ADC) for the treatment of relapsed or refractory Hodgkin lymphoma, anaplastic large cell lymphoma, and CD30-expressing mycosis fungoides.
Aug 17, 2011 - Zelboraf (vemurafenib) is a kinase inhibitor indicated for the treatment of patients with metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test, and for the treatment of patients with Erdheim-Chester Disease with BRAF V600 mutation.
Aug 11, 2011 - Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is a combination of three antiretroviral medications indicated for the once daily treatment of HIV-1 infection in treatment-naïve adults.
Aug 10, 2011 - Anascorp (Centruroides (Scorpion) Immune F(ab’)2 (Equine)) is an antivenom indicated for treatment of clinical signs of scorpion envenomation.
Jul 21, 2011 - Brilinta (ticagrelor) is a P2Y12 platelet inhibitor indicated to reduce the risk of cardiovascular events in patients with a history of heart attack, acute coronary syndrome, coronary artery disease, or stroke.
Jul 6, 2011 - Lazanda (fentanyl) is an opioid analgesic nasal spray for the management of breakthrough pain in cancer patients.
Jul 2, 2011 - Arcapta (indacaterol inhalation powder) is a long-acting beta2-agonist (LABA) for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).
Jul 2, 2011 - Xarelto (rivaroxaban) is a factor Xa inhibitor used to reduce the risk of blood clots and stroke in patients with atrial fibrillation, for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), to reduce the risk of DVT and/or PE in certain at-risk patients, for the prevention of DVT in patients undergoing knee or hip replacement surgery, for the prevention of venous thromboembolism (VTE) in acutely ill medical patients, and in combination with aspirin to reduce the risk of major cardiovascular events in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD).
Jun 29, 2011 - Rezira (hydrocodone and pseudoephedrine) Oral Solution is a combination product containing an antitussive and nasal decongestant indicated for the relief of cough and nasal congestion associated with the common cold.
Jun 29, 2011 - Zutripro (chlorpheniramine, hydrocodone and pseudoephedrine) Oral Solution is a combination product containing an antitussive, an antihistamine, and a nasal decongestant indicated for the relief of cough and nasal congestion associated with the common cold and upper respiratory allergies.
Jun 28, 2011 - Rectiv (nitroglycerin) is a topical ointment for the treatment of moderate to severe pain associated with chronic anal fissures.
Jun 21, 2011 - Oxecta (oxycodone hydrochloride) is an abuse-deterrent opioid analgesic formulation for the relief of moderate to severe pain.
Jun 16, 2011 - Nulojix (belatacept) is a selective T-cell costimulation blocker indicated for prophylaxis of organ rejection in adult patients receiving a kidney transplant.
Jun 13, 2011 - Potiga (ezogabine) is a potassium channel opener indicated for the adjunctive treatment of adults with partial-onset seizures.
May 27, 2011 - Dificid (fidaxomicin) is a macrolide antibacterial drug indicated for the treatment of Clostridium difficile-associated diarrhea.
May 21, 2011 - Edurant (rilpivirine) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated in combination with other antiretroviral drugs for the treatment of HIV-1 infection in adults who have never taken HIV therapy (treatment-naïve).
May 14, 2011 - Victrelis (boceprevir) is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated for the treatment of chronic hepatitis C.
May 3, 2011 - Tradjenta (linagliptin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
May 2, 2011 - Zytiga (abiraterone acetate) is a CYP17 inhibitor indicated for use in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.
Apr 28, 2011 - Duexis (ibuprofen and famotidine) is an NSAID and histamine H2-receptor antagonist combination indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper GI ulcers.
Apr 14, 2011 - Sylatron (peginterferon alfa-2b) is an alpha interferon indicated for the adjuvant treatment of melanoma.
Apr 11, 2011 - Caprelsa (vandetanib) is a kinase inhibitor indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable (non-operable) locally advanced or metastatic disease.
Apr 7, 2011 - Horizant (gabapentin enacarbil) is a gabapentin prodrug indicated for the once-daily treatment of moderate-to-severe primary Restless Legs Syndrome.
Mar 28, 2011 - Yervoy (ipilimumab) is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for the treatment of melanoma, renal cell carcinoma, microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, and malignant pleural mesothelioma.
Mar 15, 2011 - Gadavist (gadobutrol) is a gadolinium-based contrast agent indicated for intravenous use in diagnostic MRI in adults and children to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system.
Mar 10, 2011 - Benlysta (belimumab) is B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment of patients with active, autoantibody-positive, systemic lupus erythematosus.
Mar 1, 2011 - Daliresp (roflumilast) is an orally administered phosphodiesterase 4 (PDE4) enzyme inhibitor indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.
Feb 21, 2011 - Corifact (factor XIII concentrate (human)) is a is a fibrin-stabilizing factor concentrate indicated to prevent bleeding in people with congenital Factor XIII deficiency.
Feb 9, 2011 - Gralise (gabapentin) is an extended release, tablet formulation of the approved antiepileptic agent gabapentin, indicated for the once-daily treatment of post-herpetic neuralgia (PHN).
Feb 7, 2011 - Makena (hydroxyprogesterone caproate) is a long acting form of natural progesterone for the prevention of preterm birth in pregnant women with a history of at least one spontaneous preterm birth.
Jan 31, 2011 - DaTscan (ioflupane I 123 injection) is a radiopharmaceutical indicated for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging to assist in the evaluation of adult patients with suspected Parkinsonian syndromes (PS).
Jan 28, 2011 - Natroba (spinosad) is a pediculicide indicated for the topical treatment of head lice infestations.
Jan 25, 2011 - Viibryd (vilazodone) is a dual-acting potent and selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist indicated for the treatment of major depressive disorder (MDD).
Jan 12, 2011 - Abstral (fentanyl) is a sublingual opioid analgesic indicated for the management of breakthrough pain in cancer patients.
Jan 3, 2011 - Fortesta (testosterone) Gel is a topical androgen indicated for replacement therapy in male hypogonadism.